Una discusión sobre los medicamentos para el síndrome del cromosoma X frágil, con la Dra. Randi J. Hagerman, profesora distinguida de Pediatría, presidenta de investigación del síndrome del cromosoma X frágil e investigadora del Instituto MIND de UC Davis.
In this keynote session at the 19th NFXF International Fragile X Conference, Dr. Peter Todd discusses the history, challenges, and advancements that have helped shape the trajectory of treatments for Fragile X-associated conditions.
We asked Dr. Craig Erickson, the director of the Cincinnati Fragile X Research and Treatment Center, to answer the question, Can I use CBD to treat Fragile X syndrome? Watch as he discusses the use of cannabidiol (CBD) for people with FXS.
During this 45-minute Lunch & Learn webinar, Dr. Erickson discussed details of a single-dose medication study in Fragile X syndrome (FXS), including how the study was done, what the results showed, and moreover, why the results are important, what they mean for the FXS community, and next steps to move us forward.
Research Summary: The results found from the EEGs in both the FMR1 KO mice and humans with FXS are extremely important for the future of FXS research because they show a measurable commonality between the two very different species.
Allos Pharma announced they held a meeting with the FDA to optimize the design of their Phase 3 trial designed to support an NDA to address FXS.
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
This panel discussion is on the topic of medications and treatments available for Fragile X Syndrome.
This session will cover currently available supportive medications for treating anxiety, irritability, and agitated and aggressive behaviors that can be problematic in Fragile X syndrome. Medication classes and specific medications within each class will be described.
This session is designed for those considering starting medications for their child and/or those who would like new strategies and approaches to considering medication changes.
Jayne Dixon Weber and Dr. Craig Erickson discuss new medications and review existing medications used for various issues related to Fragile X syndrome.
Dr. Liz Berry-Kravis and Tetra Therapeutics published the BPN14770 trial results in Nature Medicine on April 29, 2021. We present a summary of those research results.
Allos Pharma, a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, has announced the exclusive license rights to arbaclofen in Fragile X syndrome.
Our distinguished presenters discuss currently available supportive medications for treating anxiety and irritable, agitated, and aggressive behaviors in Fragile X syndrome.
Our expert panel discusses and takes questions about medications.
